



Patent
HDAC-5003-U

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Xiao Yi Xiao et al.

Serial No.: 10/682,496

Filed: October 9, 2003

For: HISTONE DEACETYLASE
INHIBITORS

)
) Group Art Unit: 1626

)
) Examiner: Freistein, Andrew B.

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 CFR §§ 1.97 and 1.98, the items identified in this Information Disclosure Statement ("IDS") are brought to the attention of the Office. The items are listed on the attached form PTO-1449. As copies of U.S. patents and applications are no longer required by the Office, copies are not being submitted with this IDS. However, if the Examiner would like copies of the U.S. cited references, Applicant will provide the references upon request.

The items identified in this IDS may or may not be "material" pursuant to 37 CFR § 1.56. The submission thereof by Applicant is not to be construed as an admission that any such patent, publication or other information referred to therein is material or considered to be material (37 CFR § 1.97(h)), or even qualifies as "prior art" under 35 USC § 102 with respect to this invention unless specifically designated by Applicant as such.

02/02/2006 HDESTA1 00000008 502256 10682496


03 FC:1806 180.00 DA

CERTIFICATE OF MAILING (37 C.F.R. § 1.8)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage in an envelope addressed to the Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

January 30, 2006
Date of Deposit

Jennifer L. Sammartin
Name of Person Mailing Paper


Signature of Person Mailing Paper

INFORMATION DISCLOSURE STATEMENT FILING PROVISION:

☐ This IDS is believed to be timely in that it is being submitted under 37 CFR § 1.97(b), that is (1) within three months of the filing date of the application, which is not a continued prosecution application filed under § 1.53(d) or (2) within three months of entry of the national stage as set forth in 37 CFR § 1.491; or (3) before the mailing of a first Office action on the merits; or (4) before the mailing of a first Office action after filing a request for continued examination under § 1.114. Thus, no fee is required.

☐ However, if the undersigned is in error in this regard, Applicant respectfully requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable, and charge the fee due under 37 CFR § 1.17(p) to the deposit account referenced below.

☐ However, if the undersigned is in error in this regard, Applicant respectfully requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable, and a statement under 37 CFR § 1.97(e) is included below, thus no fee is required.

☒ This IDS is being submitted under 37 CFR § 1.97(c), that is after mailing of a first Office action on the merits, but before a Final Action under 37 CFR § 1.113 or a Notice of Allowance under 37 CFR § 1.311.

☒ The fee due under 37 CFR § 1.17(p) is submitted herewith.

☐ A statement under 37 CFR § 1.97(e) is included below, thus no fee is required. In the event that this IDS is not received before a Final Action or a Notice of Allowance, then Applicant respectfully requests that the Office consider the filing of these papers to be submitted under 37 CFR § 1.97(d) and charge the fee due under 37 CFR § 1.17(p) to the deposit account below.

☐ This IDS is being submitted under 37 CFR § 1.97(d), that is after a Final Action under 37 CFR § 1.113 or a Notice of Allowance under 37 CFR § 1.311, but before payment of the issue fee. A statement under 37 CFR § 1.97(e) is included below. The fee due under 37 CFR § 1.17(p) is submitted herewith.

STATEMENT UNDER 37 CFR § 1.97(e):

☐ Each item contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS.

☐ No item contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing

this statement after making reasonable inquiry, no item of information contained in this IDS was known to any individual designated in 37 CFR § 1.56(c) more than three months prior to the filing of this IDS.

PAYMENT AND/OR AUTHORIZATION TO CHARGE FEES:


- ☐ A check in the amount of _____ is enclosed for the above fee(s).
☒ Please charge to Deposit Account No. **50-2256** for the above fee(s).

Although Applicants do not believe any additional fees are required, the Commissioner is authorized to charge any additional fees required by the filing of these papers to Takeda's Deposit Account No. **50-2256**.


Respectfully submitted,

TAKEDA SAN DIEGO, INC.

Dated: January 30, 2006

By: 
David J. Weitz
Reg. No. 38,362

Customer No. **32793**
Takeda San Diego, Inc.
10410 Science Center
San Diego, CA 92121
Tel: (858) 622-8528
Fax: (858) 550-0992



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/682,496	
			Filing Date	October 9, 2003	
			First Named Inventor	Andrew B. Freistein	
			Group Art Unit	1626	
			Examiner Name	Not Yet Assigned	
Sheet	1	of	15	Attorney Docket Number	SYR-HDAC-5003-U

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No. ¹	Document Number	Publication Date/ Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	AA	2001/0009922	2001-07-26	Douglas V. Faller	
	AB	2001/0034367	2001-10-25	Douglas V. Faller et al.	
	AC	2002/0065282	2002-05-30	Guy Georges et al.	
	AD	2002/0076457	2002-06-20	Aylward James Harrison	
	AE	2002/0103192	2002-08-01	Michael L. Curtin et al.	
	AF	2002/0107404	2002-08-08	Olaf Prien et al.	
	AG	2002/0115826	2002-08-22	Daniel Delorme et al.	
	AH	2002/0119996	2002-08-29	Hsuan-Yin Lan-Hargest et al.	
	AI	2002/0120099	2002-08-29	Nonkazu Nishino et al.	
	AJ	2002/0132792	2002-09-19	Olaf Prien et al.	
	AK	2002/0137775	2002-09-26	Hsuan-Yin Lan-Hargest et al.	
	AL	2002/0143037	2002-10-03	Hsuan-Yin Lan-Hargest et al.	
	AM	2002/0143052	2002-10-03	Hsuan-Yin Lan-Hargest et al.	
	AN	2002/0143055	2002-10-03	Hsuan-Yin Lan-Hargest et al.	
	AO	2002/0143196	2002-10-03	Hsuan-Yin Lan-Hargest et al.	
	AP	2002/0161045	2002-10-31	Hsuan-Yin Lan-Hargest et al.	
	AQ	2002/0177594	2002-11-28	Michael L. Curtin et al.	
	AR	2002/0183513	2002-12-05	Adelbert Grossmann et al.	
	AS	2003/0013176	2003-01-16	Nikola Pavletich et al.	
	AT	2003/0013757	2003-01-16	Ulrike Leser-Reiff et al.	
	AU	2003/0017454	2003-01-23	Saraswati Sukumar et al.	
	AV	2003/0018062	2003-01-23	Stacy W. Remiszewski et al.	
	AW	2003/0049649	2003-03-13	Alan P. Wolffe et al.	
	AX	2003/0059812	2003-03-27	Victoria M. Richon et al.	
	AY	2003/0078216	2003-04-24	A. Robert MacLeod et al.	
	AZ	2003/0078369	2003-04-24	Peter T. Meinke et al.	
	BA	2003/0082668	2003-05-01	Katsuyuki Tamai et al.	
	BB	2003/0083521	2003-05-01	Hsuan-Yin Lan-Hargest et al.	
	BC	2003/0125306	2003-07-03	Hsuan-Yin Lan-Hargest et al.	
	BD	2003/0129724	2003-07-10	Christina M. Groziner et al.	
	BE	2003/0134865	2003-07-17	Ian Adcock et al.	
	BF	2003/0139404	2003-07-24	Rainer Haag et al.	
	BG	2003/0143712	2003-07-31	Eric Verdin et al.	
	BH	2003/0144276	2003-07-31	Kouichi Kikuchi et al.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/682,496	
			Filing Date	October 9, 2003	
			First Named Inventor	Andrew B. Freistein	
			Group Art Unit	1626	
			Examiner Name	Not Yet Assigned	
Sheet	2	of	15	Attorney Docket Number	SYR-HDAC-5003-U

	BI	2003/0144340	2003-07-31	Carlin Long et al.	
	BJ	2003/0148970	2003-08-07	Jeffrey M. Besterman et al.	
	BK	2003/0152557	2003-08-14	Jeffrey M. Besterman et al.	
	BL	2003/0171409	2003-09-11	Hsuan-Yin Lan-Hargest et al.	
	BM	2003/0187027	2003-10-02	Stuart L. Schreiber et al.	
	BN	2003/0212121	2003-11-13	Martin Kruger et al.	
	BO	2003/0216345	2003-11-20	Osamu Nakanishi et al.	
	BP	2003/0219832	2003-11-27	Elliott S. Klein et al.	
	BQ	2004/0002506	2004-01-01	Ronald Breslow et al.	
	BR	2004/0014647	2004-01-22	Hyang G. Woo Lee et al.	
	BS	2004/0018968	2004-01-29	George Sgouros	
	BT	2004/0023944	2004-02-05	Hsuan-Yin Lan-Hargest et al.	
	BU	2004/0024067	2004-02-05	Stacy W. Remiszewski et al.	
	BV	2004/0029903	2004-02-12	Hsuan-Yin Lan-Hargest et al.	
	BW	2004/0029922	2004-02-12	Hsuan-Yin Lan-Hargest et al.	
	BX	2004/0053820	2004-03-18	Hidekazu Nakajima et al.	
	BY	2004/0053960	2004-03-18	Guy Georges et al.	
	BZ	2004/0072735	2004-04-15	Victoria M. Richon et al.	
	CA	2004/0072770	2004-04-15	Jeffrey M. Besterman et al.	
	CB	2004/0072849	2004-04-15	Stuart L. Schreiber et al.	
	CC	2004/0077591	2004-04-22	Fernando Dangond	
	CD	2004/0077698	2004-04-22	Guy Georges et al.	
	CE	2004/0077726	2004-04-22	Clare Watkins et al.	
	CF	2004/0087631	2004-05-06	Nicholas G. Bacopoulos et al.	
	CG	2004/0087652	2004-05-06	Martin Gottlicher	
	CH	2004/0087657	2004-05-06	Victoria M. Richon et al.	
	CI	2004/0092431	2004-05-13	Peggy E. Hellberg	
	CJ	2004/0092558	2004-05-13	Peter G. Klinko	
	CK	2004/0092572	2004-05-13	Johanne Renaud et al.	
	CL	2004/0092598	2004-05-13	Clare Watkins et al.	
	CM	2004/0102458	2004-05-27	Gabriela Chiosis et al.	
	CN	2004/0106599	2004-06-03	Daniel Delorme et al.	
	CO	2004/0122079	2004-06-24	Adelbert Grossmann et al.	
	CP	2004/0122101	2004-06-24	Thomas Miller et al.	
	CQ	2004/0138270	2004-07-15	Georg Fertig et al.	
	CR	2004/0157841	2004-08-12	Georg Fertig et al.	
	CS	2004/0157924	2004-08-12	Hsuan-Yin Lan-Hargest et al.	
	CT	2004/0162317	2004-08-19	Georg Fertig et al.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/682,496
				Filing Date	October 9, 2003
				First Named Inventor	Andrew B. Freistein
				Group Art Unit	1626
				Examiner Name	Not Yet Assigned
Sheet	3	of	15	Attorney Docket Number	SYR-HDAC-5003-U

	CU	2004/0192744	2004-09-30	Rainer Haag et al.	
	CV	2004/0198830	2004-10-07	Clare J. Watkins et al.	
	CW	2004/0214862	2004-10-28	Ulrike Leser-Reiff et al.	
	CX	2004/0214880	2004-10-28	Georg Fertig et al.	
	CY	2004/0224991	2004-11-11	Xian-Ping Lu et al.	
	CZ	2004/0229889	2004-11-18	Yasuharu Urano et al.	
	DA	2004/0254220	2004-12-16	Jerome C. Bressi et al.	
	DB	2004/0266769	2004-12-30	Jerome C. Bressi et al.	
	DC	2004/0266818	2004-12-30	Ronald Breslow et al.	
	DD	2005/0014839	2005-01-20	Alan Kozikowski et al.	
	DE	2005/0026907	2005-02-03	Paul Wash et al.	
	DF	2005/0032794	2005-02-10	Jana K. Padia et al.	
	DG	2005/0032831	2005-02-10	Alan Kozikowski et al.	
	DH	2005/0079995	2005-04-14	Antonio Bedaloy et al.	
	DI	2005/0085507	2005-04-21	Stacy W. Remiszewski et al.	
	DJ	2005/0085515	2005-04-21	Clare J. Watkins et al.	
	DK	2005/0096468	2005-05-05	Kristof Van Emelen et al.	
	DL	2005/0107348	2005-05-19	Hsuan-Yin Lan-Hargest et al.	
	DM	2005/0107384	2005-05-19	Patrick Angibaud et al.	
	DN	2005/0107445	2005-05-19	Clare J. Watkins et al.	
	DO	2005/0113373	2005-05-26	Kristof Van Emelen et al.	
	DP	2005/0119250	2005-06-02	Patrick Angibaud et al.	
	DQ	2005/0124679	2005-06-09	Dae-Kee Kim et al.	
	DR	2005/0131018	2005-06-16	Martin Sendzik et al.	
	DS	2005/0137232	2005-06-23	Jerome C. Bressi et al.	
	DT	2005/0137234	2005-06-23	Jerome C. Bressi et al.	
	DU	2005/0143385	2005-06-30	Clare J. Watkins et al.	
	DV	2005/0148613	2005-07-07	Kristof Van Emelen	
	DW	2005/0159470	2005-07-21	Jerome C. Bressi et al.	
	DX	2005/0165016	2005-07-28	Kristof Van Emelen	
	DY	2005/0171103	2005-08-04	Elaine Sophie Elizabeth Stokes et al.	
	DZ	2005/0171208	2005-08-04	Hsuan-Yin Lan-Hargest et al.	
	EA	2005/0171347	2005-08-04	Kristof Van Emelen	
	EB	2005/0176686	2005-08-11	Alexander B. Maurer et al.	
	EC	4,482,571	1984-11-13	Donald J. Abraham	
	ED	5,124,342	1992-06-23	Francis A.J. Kerdesky et al.	
	EE	5,216,004	1993-06-01	Susan P. Perrine	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/682,496		
		Filing Date	October 9, 2003		
		First Named Inventor	Andrew B. Freistein		
		Group Art Unit	1626		
		Examiner Name	Not Yet Assigned		
Sheet	4	of	15	Attorney Docket Number	SYR-HDAC-5003-U

EF	5,439,939	1995-08-08	Susan P. Perrine
EG	5,645,852	1997-07-08	Harold L. Newmark
EH	5,656,644	1997-08-12	Jerry L. Adams et al.
EI	5,700,826	1997-12-23	Adnan Mjalli et al.
EJ	5,858,365	1999-01-12	Douglas V. Faller
EK	5,922,837	1999-07-13	Peter T. Meinke et al.
EL	5,939,455	1999-08-17	Ada Rephaeli
EM	5,939,456	1999-08-17	Susan P. Perrine
EN	6,011,000	2000-01-04	Susan P. Perrine
EO	6,030,961	2000-02-29	Abraham Nudelman et al.
EP	6,040,342	2000-03-21	Ada Rephaeli et al.
EQ	6,043,277	2000-03-28	Ada Repaeli et al.
ER	6,043,389	2000-03-28	Abraham Nudelman et al.
ES	6,068,987	2000-05-30	Paula M. Dulski et al.
ET	6,110,697	2000-08-29	Paula M. Dulski et al.
EU	6,110,955	2000-08-29	Abraham Nudelman et al.
EV	6,110,970	2000-08-29	Abraham Nudelman et al.
EW	6,124,495	2000-09-26	Edward Neiss et al.
EX	6,130,248	2000-10-10	Abraham Nudelman et al.
EY	6,174,905	2001-01-16	Tsuneji Suzuki et al.
EZ	6,197,743	2001-03-06	Douglas V. Faller
FA	6,231,880	2001-05-15	Susan P. Perrine
FB	6,239,176	2001-05-29	Abraham Nudelman et al.
FC	6,262,116	2001-07-17	Pier Paolo Pandolfi et al.
FD	6,329,402	2001-12-11	Kouichi Kikuchi et al.
FE	6,387,673	2002-05-14	Ronald M. Evans et al.
FF	6,399,568	2002-06-04	Norikazu Nishino et al.
FG	6,403,555	2002-06-11	Soren Skov
FH	6,495,719	2002-12-17	Hsuan-Yin Lan-Hargest et al.
FI	6,511,990	2003-01-28	Ronald Breslow et al.
FJ	6,512,123	2003-01-28	Adelbert Grossmann et al.
FK	6,531,472	2003-03-11	Guy Georges et al.
FL	6,538,030	2003-03-25	Yih-Lin Chang et al.
FM	6,541,661	2003-04-01	Daniel Delorme et al.
FN	6,544,957	2003-04-08	Scott E. Kern et al.
FO	6,548,479	2003-04-15	Soren Skov
FP	6,552,065	2003-04-22	Stacy W. Remiszewski et al.
FQ	6,562,995	2003-05-13	Hsuan-Yin Lan-Hargest et al.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/682,496	
			Filing Date	October 9, 2003	
			First Named Inventor	Andrew B. Freistein	
			Group Art Unit	1626	
			Examiner Name	Not Yet Assigned	
Sheet	5	of	15	Attorney Docket Number	SYR-HDAC-5003-U

	FR	6,599,937	2003-07-29	Edward Neiss et al.	
	FS	6,638,530	2003-10-28	Masahiko Ishibashi et al.	
	FT	6,656,905	2003-12-02	Hiroaki Mori et al.	
	FU	6,667,341	2003-12-23	Hsuan-Yin Lan-Hargest et al.	
	FV	6,693,132	2004-02-17	Hsuan-Yin Lan-Hargest et al.	
	FW	6,699,902	2004-03-02	Hsuan-Yin Lan-Hargest et al.	
	FX	6,706,686	2004-03-16	Carlin Long et al.	
	FY	6,720,445	2004-04-13	Hsuan-Yin Lan-Hargest et al.	
	FZ	6,784,173	2004-08-31	Ulrike Leser-Reiff et al.	
	GA	6,800,638	2004-10-05	Guy Georges et al.	
	GB	6,825,317	2004-11-30	Norikazu Nishino et al.	
	GC	6,828,302	2004-12-07	Soren Skov	
	GD	6,831,061	2004-12-14	Hyang Woo Lee et al.	
	GE	6,833,384	2004-12-21	Stacy W. Remiszewski et al.	
	GF	6,841,565	2005-01-11	David M. Lucas et al.	
	GG	6,869,953	2005-03-22	Rainer Haag et al.	
	GH	6,888,027	2005-05-03	Ulrike Leser-Reiff et al.	
	GI	6,897,220	2005-05-24	Daniel Delorme et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	GJ	WO/0008048	2000-02-17	FUJISAWA PHARMACEUTICAL CO., LTD.		
	GK	WO/00021979	2000-04-20	FUJISAWA PHARMACEUTICAL CO., LTD.		
	GL	WO/00052033	2000-09-08	JAPAN ENERGY CORPORATION		
	GM	WO/00071703	2000-11-30	METHYLGENE INC.		
	GN	WO/00107042	2001-02-01	MERCK & CO., INC.		
	GO	WO/00118171	2001-03-15	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH		
	GP	WO/00127314	2001-04-19	MERCK & CO., INC.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/682,496		
		Filing Date	October 9, 2003		
		First Named Inventor	Andrew B. Freistein		
		Group Art Unit	1626		
		Examiner Name	Not Yet Assigned		
Sheet	6	of	15	Attorney Docket Number	SYR-HDAC-5003-U

	GQ	WO/00138322	2001-05-31	METHYLGENE, INC.		
	GR	WO/00207722	2002-01-31	GEORG-SPEYER-HAUS		
	GS	WO/00215921	2002-02-28	THE GOVERNEMENT OF THE UNITED STATES OF AMERICA,		
	GT	WO/00222133	2002-03-21	VIRGINIA COMMONWEALTH UNIVERSITY		
	GU	WO/00226696	2002-04-04	PROLIFIX LIMITED		
	GV	WO/00226703	2002-04-04	PROLIFIX LIMITED		
	GW	WO/00230879	2002-04-18	PROLIFIX LIMITED		
	GX	WO/0061576	2000-10-19	SMITHKLINE BEECHAM CORPORATION		
	GY	WO/0107042	2001-02-01	MERCK & CO., INC.		
	GZ	WO/0116106	2001-03-08	SCHERING AKTIENGESELLSCHAFT		
	HA	WO/0118045	2001-03-15	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH		
	HB	WO/0118171	2001-03-15	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH		
	HC	WO/0127314	2001-04-19	MERCK & CO., INC.		
	HD	WO/0138322	2001-05-31	METHYLGENE, INC.		
	HE	WO/0142437	2001-06-14	AXYS PHARMACEUTICALS, INC.		
	HF	WO/0170675	2001-09-27	METHYLGENE, INC.		
	HG	WO/0172737	2001-10-04	SMITHKLINE BEECHAM CORPORATION		
	HH	WO/02051842	2002-07-04	F. HOFFMANN-LA ROCHE AG		
	HI	WO/02055017	2002-07-18	WAKE FOREST UNIVERSITY		
	HJ	WO/02055688	2002-07-18	THE GOVERNMENT OF THE UNITED STATES OF AMERICA,		
	HK	WO/02062773	2002-08-15	F. HOFFMANN-LA ROCHE AG		
	HL	WO/0206307	2002-01-24	FUJISAWA PHARMACEUTICAL CO., LTD.		
	HM	WO/02069947	2002-09-12	METHYLGENE, INC.		
	HN	WO/02076941	2002-10-03	CIRCAGEN PHARMACEUTICAL		
	HO	WO/0207722	2002-01-31	GEORG-SPEYER-HAUS		
	HP	WO/02083173	2002-10-24	DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS		
	HQ	WO/02085400	2002-10-31	SUPERGEN, INC.		
	HR	WO/02085883	2002-10-31	F. HOFFMANN-LA ROCHE AG		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/682,496		
		Filing Date	October 9, 2003		
		First Named Inventor	Andrew B. Freistein		
		Group Art Unit	1626		
		Examiner Name	Not Yet Assigned		
Sheet	7	of	15	Attorney Docket Number	SYR-HDAC-5003-U

	HS	WO/02089782	2002-11-14	PRESIDENT AND FELLOWS OF HARVARD COLLEGE		
	HT	WO/02102316	2002-12-27	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA		
	HU	WO/02102323	2001-01-11	STUDIENGESELLSCHAFT KOHLE MBH		
	HV	WO/0222577	2002-03-21	NOVARTIS AG		
	HW	WO/0226696	2002-04-04	PROLIFIX LIMITED		
	HX	WO/0226703	2002-04-04	PROLIFIX LIMITED		
	HY	WO/0230879	2002-04-18	PROLIFIX LIMITED		
	HZ	WO/0236075	2002-05-10	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH		
	IA	WO/0246129	2002-06-13	ABBOTT LABORATORIES		
	IB	WO/0246144	2002-06-13	F. HOFFMANN-LA ROCHE AG		
	IC	WO/0246171	2002-06-13	SIGNAL PHARMACEUTICALS, INC.		
	ID	WO/0250244	2002-06-27	ISIS PHARMACEUTICALS, INC.		
	IE	WO/0250285	2002-06-27	NOVARTIS AG		
	IF	WO/03006652	2003-01-23	METHYLGENE, INC.		
	IG	WO/03011851	2003-02-13	F. HOFFMAN-LA ROCHE AG		
	IH	WO/03013493	2003-02-20	ITALFARMACO S.P.A.		
	II	WO/03014340	2003-02-20	NOVARTIS AG		
	IJ	WO/03024442	2003-03-27	G2M CANCER DRUGS AG		
	IK	WO/03024448	2003-03-27	METHYLGENE, INC.		
	IL	WO/03032921	2003-04-24	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH		
	IM	WO/03039599	2003-05-15	NOVARTIS AG		
	IN	WO/03053468	2003-07-03	UNIVERSITE LIBRE DE BRUXELLES		
	IO	WO/03057722	2003-07-17	FUJISAWA PHARMACEUTICAL CO., LTD.		
	IP	WO/03059864	2003-07-24	SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.		
	IQ	WO/03066579	2003-08-14	AXYS PHARMACEUTICALS		
	IR	WO/03066885	2003-08-14	NOVARTIS AG		
	IS	WO/03070188	2003-08-28	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH		
	IT	WO/03070691	2003-08-28	OSAKA INDUSTRIAL PROMOTION ORGANIZATION		
	IU	WO/03070754	2003-08-28	Minoru YOSHIDA et al.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/682,496		
		Filing Date	October 9, 2003		
		First Named Inventor	Andrew B. Freistein		
		Group Art Unit	1626		
		Examiner Name	Not Yet Assigned		
Sheet	8	of	15	Attorney Docket Number	SYR-HDAC-5003-U

	IV	WO/03075839	2003-09-18	ATON PHARMA, INC.		
	IW	WO/03075929	2003-09-18	JANSSEN PHARMACEUTICA N.V.		
	IX	WO/03076395	2003-09-18	JANSSEN PHARMACEUTICA N.V.		
	IY	WO/03076400	2003-09-18	JANSSEN PHARMACEUTICA N.V.		
	IZ	WO/03076401	2003-09-18	JANSSEN PHARMACEUTICA N.V.		
	JA	WO/03076421	2003-09-18	JANSSEN PHARMACEUTICA N.V.		
	JB	WO/03076422	2003-09-18	JANSSEN PHARMACEUTICA N.V.		
	JC	WO/03076430	2003-09-18	JANSSEN PHARMACEUTICA N.V.		
	JD	WO/03076438	2003-09-18	JANSSEN PHARMACEUTICA N.V.		
	JE	WO/03082288	2003-10-09	PROLIFIX LIMITED		
	JF	WO/03083067	2003-10-09	BRIGHAM AND WOMEN'S HOSPITAL, INC.		
	JG	WO/03084611	2003-10-16	FUJISAWA PHARMACEUTICAL CO., LTD.		
	JH	WO/03086397	2003-10-23	KOWA CO., LTD.		
	JI	WO/03087057	2003-10-23	ASTRAZENECA AB		
	JJ	WO/03087066	2003-10-23	SK CHEMICALS, CO., LTD.		
	JK	WO/03088954	2003-10-30	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH		
	JL	WO/03092686	2003-11-13	ASTRAZENECA AB		
	JM	WO/03099272	2003-12-04	BEACON LABORATORIES, INC.		
	JN	WO/03099760	2003-12-04	BEACON LABORATORIES, INC.		
	JO	WO/03099789	2003-12-04	BEACON LABORATORIES, INC.		
	JP	WO/04002944	2004-01-08	PHARMACIA & UPJOHN COMPANY		
	JQ	WO/04017996	2004-03-04	YAMANOUCHI PHARMACEUTICAL CO.		
	JR	WO/04024160	2004-03-25	VIRGINIA COMMONWEALTH UNIVERSITY		
	JS	WO/04026234	2004-04-01	UNIVERSITY OF SOUTH FLORIDA		
	JT	WO/04052838	2004-06-24	F. HOFFMANN-LA ROCHE AG		
	JU	WO/04053140	2004-06-24	JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/682,496
				Filing Date	October 9, 2003
				First Named Inventor	Andrew B. Freistein
				Group Art Unit	1626
				Examiner Name	Not Yet Assigned
Sheet	9	of	15	Attorney Docket Number	SYR-HDAC-5003-U

	JV	WO/04054999	2004-07-01	F. HOFFMANN-LA ROCHE AG		
	JW	WO/04063146	2004-07-29	ITALFARMACO SPA		
	JX	WO/04063169	2004-07-29	FUJISAWA PHARMACEUTICAL CO., LTD.		
	JY	WO/04065354	2004-08-05	TOPOTARGET UK LIMITED		
	JZ	WO/04067480	2004-08-12	OXFORD GLYCOSCIENCES (UK) LTD		
	KA	WO/04069823	2004-08-19	METHYLGENE, INC.		
	KB	WO/04076386	2004-09-10	TOPOTARGET UK LIMITED		
	KC	WO/04082638	2004-09-30	SYRRX, INC.		
	KD	WO/04092115	2004-10-28	AXYS PHARMACEUTICALS INC.		
	KE	WO/04110418	2004-12-23	KALYPSYS, INC.		
	KF	WO/04113336	2004-12-29	CHROMA THERAPEUTICS LIMITED		
	KG	WO/04113366	2004-12-29	RIKEN		
	KH	WO/05004861	2005-01-20	KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY		
	KI	WO/05011661	2005-02-10	UNIVERSITY COLLEGE LONDON		
	KJ	WO/05014588	2005-02-17	ARGENTA DISCOVERY LIMITED		
	KK	WO/05016264	2005-02-24	AVALON PHARMACEUTICALS		
	KL	WO/05018578	2005-03-03	ATON PHARMA, INC.		
	KM	WO/05019174	2005-03-03	AXYS PHARMACEUTICALS, INC.		
	KN	WO/05028447	2005-03-31	S'BIO PTE LTD		
	KO	WO/05030704	2005-04-07	METHYLGENE, INC.		
	KP	WO/05030705	2005-04-07	METHYLGENE, INC.		
	KQ	WO/05034880	2005-04-21	ATON PHARMA, INC.		
	KR	WO/05039498	2005-05-06	ATON PHARMA, INC.		
	KS	WO/05040101	2005-05-06	S'BIO PTE LTD		
	KT	WO/05040161	2005-05-06	S'BIO PTE LTD		
	KU	WO/05047457	2005-05-26	JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH		
	KV	WO/05051901	2005-06-09	THE UNIVERSITY OF QUEENSLAND		
	KW	WO/05053610	2005-06-16	ATON PHARMA, INC.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/682,496
				Filing Date	October 9, 2003
				First Named Inventor	Andrew B. Freistein
				Group Art Unit	1626
				Examiner Name	Not Yet Assigned
Sheet	10	of	15	Attorney Docket Number	SYR-HDAC-5003-U

	KX	WO/05055928	2005-06-23	THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION		
	KY	WO/05058298	2005-06-30	WISCONSIN ALUMNI RESEARCH FOUNDATION		
	KZ	WO/05058803	2005-06-30	EXONHIT THERAPEUTICS SA		
	LA	WO/05065681	2005-07-21	SYRRX, INC.		
	LB	WO/05066151	2005-07-21	SYRRX, INC.		
	LC	WO/09711366	1997-03-27	MERCK & CO., INC.		
	LD	WO/09735990	1997-10-02	PRESIDENT AND FELLOWS OF HARVARD COLLEGE		
	LE	WO/09747307	1997-12-18	THE UAB RESEARCH FOUNDATION		
	LF	WO/09800127	1998-01-08	Ada REPHAELI		
	LG	WO/9826773	1998-06-25	WARNER-LAMBERT COMPANY		
	LH	WO/9829114	1998-07-09	BEACON LABORATORIES L.L.C.		
	LI	WO/9839966	1998-09-17	BEACON LABORATORIES, L.L.C.		
	LJ	WO/9840065	1998-09-17	BEACON LABORATORIES, L.L.C.		
	LK	WO/9840080	1998-09-17	BEACON LABORATORIES, L.L.C.		
	LL	WO/09911659	1999-03-11	JAPAN ENERGY CORPORATION		
	LM	WO/09923885	1999-05-20	THE SALK INSTITUTE FOR BIOLOGICAL STUDIES		
	LN	WO/2002076941	2002-10-03	CIRCAGEN PHARMACEUTICAL		
	LO	WO/2003006652	2003-01-23	METHYLGENE, INC.		
	LP	WO/2004/002944	2004-01-08	PHARMACIA & UPJOHN COMPANY		
	LQ	WO/2004005282	2004-01-15	NOVARTIS AG		
	LR	WO/2004005513	2004-01-15	METHYLGENE, INC.		
	LS	WO/2004009536	2004-01-29	4SC AG		
	LT	WO/2004013130	2004-02-12	ARGENTA DISCOVERY LIMITED		
	LU	WO/2004/017996	2004-03-04	YAMANOUCI PHARMACEUTICAL CO., LTD.		
	LV	WO/2004020460	2004-03-11	YAMANOUCI PHARMACEUTICAL CO., LTD.		
	LW	WO/2004024160	2004-03-25	VIRGINIA COMMONWEALTH UNIVERSITY		
	LX	WO/2004026234	2004-04-01	UNIVERSITY OF SOUTH FLORIDA		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/682,496		
		Filing Date	October 9, 2003		
		First Named Inventor	Andrew B. Freistein		
		Group Art Unit	1626		
		Examiner Name	Not Yet Assigned		
Sheet	11	of	15	Attorney Docket Number	SYR-HDAC-5003-U

	LY	WO/2004035525	2004-04-29	METHYLGENE INC.		
	MA	WO/2004043348	2004-05-27	ALCON, INC.		
	MB	WO/2004043352	2004-05-27	ALCON, INC.		
	MC	WO/2004046094	2004-06-03	QUEEN MARY & WESTFIELD COLLEGE		
	MD	WO/2004046104	2004-06-03	BEACON LABORATORIES		
	ME	WO/2004069133	2004-08-19	F. HOFFMANN-LA ROCHE AG		
	MF	WO/2004069803	2004-08-19	F. HOFFMANN-LA ROCHE AG		
	MG	WO/2004069823	2004-08-19	METHYLGENE, INC.		
	MH	WO/2004071400	2004-08-26	SHENZHEN CHIPSCREEN BIOSCIENCES LTD.		
	MI	WO/2004071401	2004-08-26	FUJISAWA PHARMACEUTICAL CO., LTD.		
	MJ	WO/9307124	1993-04-15	EISAI CO., LTD.		
	MK	WO/9615096	1996-05-23	BAYER CORPORATION		
	ML	WO/9702244	1997-01-23	Kouichi KIKUCHI		
	MM	WO/9828269	1998-07-02	THE DUPONT MERCK PHARMACEUTICAL COMPANY		
	MN	WO/9961413	1999-12-02	BAYER CORPORATION		
	MO	EP/0847992	1998-06-17	MITSUI CHEMICALS, INC.		

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	MP	BOUCHAIN, GILIANE et al., Development of Potential Antitumor Agents. Synthesis and Biological Evaluation of a New Set of Sulfonamide Derivatives as Histone Deacetylase Inhibitors, Journal of Medicinal Chemistry, (2003) Vol. 46, pp. 820-830, American Chemical Society	
	MQ	CAMPHAUSEN, K. et al., Enhanced Radiation-Induced Cell Killing and Prolongation of γ H2AX Foci Expression by the Histone Deacetylase Inhibitor MS-275, Cancer Research, (01/01/2004), Vol. 64, pp. 316-321, Maryland.	
	MR	CATLEY, L. et al., NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma, Blood, (10/01/2003), Vol. 102(7), pp. 2615-22, Epub.	
	MS	COLLETTI, STEVEN L. et al., Broad Spectrum Antiprotozoal Agents that Inhibit Histone Deacetylase: Structure—Activity Relationships of Apicidin. Part 1 and Part 2, Bioorganic & Medicinal Chemistry Letters, (2001), Vol. 11, pp. 107-111, Elsevier Science Ltd.	
	MT	CURTIN, MICHAEL et al., Histone Deacetylase Inhibitors: The Abbott Experience, Current Medicinal Chemistry, (2003), Vol. 10, 1241-1253, Bentham Science Publishers Ltd.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO <h2 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center;">(use as many sheets as necessary)</p>		<h3 style="text-align: center;">Complete if Known</h3> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td>10/682,496</td> </tr> <tr> <td>Filing Date</td> <td>October 9, 2003</td> </tr> <tr> <td>First Named Inventor</td> <td>Andrew B. Freistein</td> </tr> <tr> <td>Group Art Unit</td> <td>1626</td> </tr> <tr> <td>Examiner Name</td> <td>Not Yet Assigned</td> </tr> <tr> <td>Attorney Docket Number</td> <td>SYR-HDAC-5003-U</td> </tr> </table>		Application Number	10/682,496	Filing Date	October 9, 2003	First Named Inventor	Andrew B. Freistein	Group Art Unit	1626	Examiner Name	Not Yet Assigned	Attorney Docket Number	SYR-HDAC-5003-U
Application Number	10/682,496														
Filing Date	October 9, 2003														
First Named Inventor	Andrew B. Freistein														
Group Art Unit	1626														
Examiner Name	Not Yet Assigned														
Attorney Docket Number	SYR-HDAC-5003-U														
Sheet	12	of	15												

MU	DAI, YUJIA et al., Indole Amide Hydroxamic Acids as Potent Inhibitors of Histone Deacetylase, Bioorganic and Medicinal Chemistry Letters, (2003), pp. 1-5, Abbott Park, IL.
MV	DARKIN-RATTRAY, SANDRA J. et al., Apicidin: A novel antiprotozoal agent that inhibits parasite histone deacetylase, Proceedings of the National Academy of Sciences, (November 1996), Vol. 93, pp.13143-14147, West Point, PA.
MW	FOURNEL, MARIELLE et al., Sulfonamide Anilides, a Novel Class of Histone Deacetylase Inhibitors, Are Antiproliferative against Human Tumors, Cancer Research, (08/01/2002), Vol. 62, pp. 4325-4330, Quebec, Canada.
MX	FREY, ROBIN R. et al., Trifluoromethyl Ketones as Inhibitors of Histone Deacetylase, Bioorganic & Medicinal Chemistry Letters, (2002), pp. 3443-3447.
MY	FURUMAI, RYOHEI et al., Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin, Proceedings of the National Academy of Sciences, (01/02/2001), Vol. 98, No. 1, pp. 87-92, New York, NY.
MZ	GLASER, KEITH B. et al., Gene Expression Profiling of Multiple Histone Deacetylase (HDAC) Inhibitors: Defining a Common Gene Set Produced by HDAC Inhibition in T24 and MDA Carcinoma Cell Lines, Molecular Cancer Therapeutics, (2003), Vol. 2, pp. 151-163.
NA	GROZINGER, CHRISTINA et al., Deacetylase Enzymes: Biological Functions and the Use of Small-Molecule Inhibitors, Chemistry & Biology, (2002), Vol. 9, pp. 3 -16, Elsevier Science Ltd.
NB	HAGGARTY, STEPHEN J. et al., Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation, Proceedings of the National Academy of Sciences, (04/15/2003) Vol. 100, No. 8, pp. 4389-4394.
NC	HU, ERDING et al., Identification of Novel Isoform-Selective Inhibitors within Class I Histone Deacetylases, The Journal of Pharmacology and Experimental Therapeutics, (2003), Vol. 307, No. 2, pp. 720-728, The American Society for Pharmacology and Experimental Therapeutics.
ND	JABOIN, JERRY et al., MS-27-275, an Inhibitor of Histone Deacetylase, Has Marked in Vitro and in Vivo Antitumor Activity against Pediatric Solid Tumors, Cancer Research, (11/01/2002), Vol. 62, pp. 6108-6115.
NE	JOSE, BINOY et al., Toward an HDAC6 Inhibitor: synthesis and conformational analysis of cyclic hexapeptide hydroxamic acid designed from α -tubulin sequence Toward an HDAC6 Inhibitor: synthesis and conformational analysis of cyclic hexapeptide hydroxamic acid designed from α -tubulin sequence, Bioorganic & Medicinal Chemistry, (2004), Vol. 12, pp. 1351-1356, Elsevier Ltd.
NF	JUNG, MANFRED et al., Amide Analogues of Trichostatin A as Inhibitors of Histone Deacetylase and Inducers of Terminal Cell Differentiation, Journal of Medicinal Chemistry, (1999), Vol. 42, 4669-4679, American Chemical Society.
NG	KAPUSTIN, GALINA V. et al., Phosphorus-Based SAHA Analogues as Histone Deacetylase Inhibitors, Organic Letters, (2003), Vol. 0, No. 0, pp. A-D, American Chemical Society.
NH	KOMATSU, YASUHIKO et al., Cyclic Hydroxamic-acid-containing Peptide 31, a Potent Synthetic Histone Deacetylase Inhibitor with Antitumor Activity, Cancer Research, (06/01/2001), Vol. 61, pp. 4459-4466.
NI	KRAKER, ALAN J. et al., Modulation of Histone Acetylation by [4-(Acetylamino)-N-(2-Amino-phenyl) Benzamide] in HCT-8 Colon Carcinoma, Molecular Cancer Therapeutics, (2003), Vol. 2, pp. 401-408.
NJ	LAVOIE, RICO et al., Design and Synthesis of a Novel Class of Histone Deacetylase Inhibitors, Bioorganic & Medicinal Chemistry Letters, (2001), Vol. 11, pp. 2847-2850, Elsevier Science Ltd.

Examiner Signature	Date Considered	
--------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/682,496		
		Filing Date	October 9, 2003		
		First Named Inventor	Andrew B. Freistein		
		Group Art Unit	1626		
		Examiner Name	Not Yet Assigned		
Sheet	13	of	15	Attorney Docket Number	SYR-HDAC-5003-U

NK	LEE, BYOUNG ICK et al., MS-275, A Histone Deacetylase Inhibitor, Selectively Induces Transforming Growth Factor β Type II Receptor Expression in Human Breast Cancer Cells, Cancer Research, (02/01/2001), Vol. 61, pp. 931-934.
NL	LU, QIANG et al., Zn^{2+} -Chelating, Motif-Tethered, Short-Chain Fatty Acids as a Novel Class of Histone Deacetylase Inhibitors, Journal of Medicinal Chemistry, (2004), Vol. 47, pp. 467-474, American Chemical Society.
NM	MAGGIO, SONIA C., The Histone Deacetylase Inhibitor MS-275 Interacts Synergistically with Fludarabine to Induce Apoptosis in Human Leukemia Cells, Cancer Research, (04/01/2004), Vol. 64, pp. 2590-2600.
NN	MAI, ANTONELLO et al., Binding Mode Analysis of 3-(4-Benzoyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamide: a New Synthetic Histone Deacetylase Inhibitor Inducing Histone Hyperacetylation, Growth Inhibition, and Terminal Cell Differentiation, Journal of Medicinal Chemistry, (2002), Vol. 45, pp. 1778-1784, American Chemical Society.
NO	MAI, ANTONELLO et al., 3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-alkylamides as a New Class of Synthetic Histone Deacetylase Inhibitors. 1. Design, Synthesis, Biological Evaluation, and Binding Mode Studies Performed through Three Different Docking Procedures, Journal of Medicinal Chemistry, (2003), Vol. 46, pp. 512-524, American Chemical Society.
NP	MAI, ANTONELLO et al., 3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-alkylamides as a New Class of Synthetic Histone Deacetylase Inhibitors. 2. Effect of Pyrrole- C_2 and/or - C_4 Substitutions on Biological Activity, Journal of Medicinal Chemistry, (2003), pp. A-L, American Chemical Society.
NQ	MAI, ANTONELLO et al., Discovery of (Aryloxopropenyl)pyrrolyl Hydroxyamides as Selective Inhibitors of Class IIa Histone Deacetylase Homologue HD1-A, Journal of Medicinal Chemistry, (2003), pp. A-D, American Chemical Society.
NR	MARKS, PAUL A. et al., Histone Deacetylase Inhibitors as New Cancer Drugs, Current Opinion in Oncology, (2001), Vol. 13, pp. 477-483, Lippincott Williams & Wilkins, Inc.
NS	MASSA, SILVIO et al., 3-(4-Aroyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides, a New Class of Synthetic Histone Deacetylase Inhibitors, Journal of Medicinal Chemistry, (2001), Vol. 44, pp. 2069-2072, American Chemical Society.
NT	MEINKE, PETER et al., Synthesis of Apicidin-Derived Quinolone Derivatives: Parasite-Selective Histone Deacetylase Inhibitors and Antiproliferative Agents, Journal of Medicinal Chemistry, (2000), Vol. 43, pp. 4919-4922, American Chemical Society.
NU	MILLER, THOMAS A. et al., Histone Deacetylase Inhibitors, Journal of Medicinal Chemistry, (11/20/2003), Vol. 46, No. 24, pp. 5097-5116, American Chemical Society.
NV	NISHINO, NORIKAZU et al., Cyclic Tetrapeptides Bearing a Sulfhydryl Group Potently Inhibit Histone Deacetylase, Organic Letters, (2003), Vol. 0, No. 0, pp. A-D, American Chemical Society.
NW	PINA, IVETTE C. et al., Psammaplins from the Sponge Pseudoceratina purpurea: Inhibition of Both Histone Deacetylase and DNA Methyltransferase, Journal of Organic Chemistry, (02/24/2003), pp. A-H, American Chemical Society.
NX	PLUMB, JANE et al., Pharmacodynamic Response and Inhibition of Growth of Human Tumor Xenografts by the Novel Histone Deacetylase Inhibitor PXD101, Molecular Cancer Therapeutics, (August 2003), Vol. 2, pp. 721-728.
NY	PRAKASH, SUCHARU et al., Chronic oral administration of CI-994: a Phase 1 Study, Investigational New Drugs, (2001), Vol. 19, pp. 1-11, Kluwer Academic Publishers, Netherlands.

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/682,496		
		Filing Date	October 9, 2003		
		First Named Inventor	Andrew B. Freistein		
		Group Art Unit	1626		
		Examiner Name	Not Yet Assigned		
Sheet	14	of	15	Attorney Docket Number	SYR-HDAC-5003-U

NZ	RAGNO, RINO et al., 3-(4-Aroyl-1-methyl-1 H-pyrrol-2-yl)-N-hydroxy-2-propenamides as a New Class of Synthetic Histone Deacetylase Inhibitors. 3. Discovery of New Lead Compounds through Structure-Based Drug Design and Docking Studies, Journal of Medicinal Chemistry, (2004), Vol. 47, pp. 1351-1359, American Chemical Society.
OA	REMISZEWSKI, STACY et al., Inhibitors of Human Histone Deacetylase: Synthesis and Enzyme and Cellular Activity of Straight Chain Hydroxamates, Journal of Medicinal Chemistry, (02/14/2002), Vol. 45, No. 4, pp. 753-757, American Chemical Society.
OB	REMISZEWSKI, STACY, Recent Advances in the Discovery of Small Molecule Histone Deacetylase Inhibitors, Current Opinion Drug Discovery Development, (07/05/2002), "abstract."
OC	REMISZEWSKI, STACY et al., N-Hydroxy-3-phenyl-2-propenamides as Novel Inhibitors of Human Histone Deacetylase with in Vivo Antitumor Activity: Discovery of (2E)-N-Hydroxy-3-[4-[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl-phenyl]-2-propenamide (NVP-LAQ824), Journal of Medicinal Chemistry, (05/15/2003), pp. A-P, American Chemical Society.
OD	REMISZEWSKI, STACY, The Discovery of NVP-LAQ824: From Concept to Clinic, Current Medicinal Chemistry, (11/10/2003), "abstract"
OE	ROSATO, ROBERTO R., The Histone Deacetylase Inhibitor MS-275 Promotes Differentiation or Apoptosis in Human Leukemia Cells through a Process Regulated by Generation of Reactive Oxygen Species and Induction of p21 ^{CIP1/WAF1} , Cancer Research, (07/01/2003), Vol. 63, pp. 3637-3645.
OF	SAITO, AKIKO et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors, Proceedings of the National Academy of Sciences, (April 1999), Vol. 96, pp. 4592-4597.
OG	SINGH, SHEO et al., Structure, Histone Deacetylase, and Antiprotozoal Activities of Apidicidins B and C, Congeners of Apidicin with Praline and Valine Substitutions., Organic Letters, (09/06/2001), "abstract."
OH	SINGH, SHEO et al., Structure and Chemistry of Apidicidins, a Class of Novel Cyclic Tetrapeptides without a Terminal α -Keto Epoxide as Inhibitors of Histone Deacetylase with Potent Antiprotozoal Activities, Journal of Organic Chemistry, (2002), Vol. 67, pp. 815-825, American Chemical Society.
OI	Sternson, Scott et al., Synthesis of 7200 Small Molecules Based on a Substructural Analysis of the Histone Deacetylase Inhibitors Trichostatin and Trapoxin, Organic Letters, (2001), Vol. 3, pp. 4239-4242, American Chemical Society.
OJ	SU, GLORIA et al., A Novel Histone Deacetylase Inhibitor Identified by High-Throughput Transcriptional Screening of a Compound Library, Cancer Research, (06/15/2000), Vol. 60, pp. 3137-3142.
OK	SUZUKI, TAKAYOSHI et al., Novel Histone Deacetylase Inhibitors: Design, Synthesis, Enzyme Inhibition, and Binding Mode Study of SAHA-Based Non-hydroxamates, Bioorganic & Medicinal Chemistry Letters, (2003), Vol. 13, pp. 4321-4326, Elsevier Ltd.
OL	SUZUKI, TSUNEJI et al., Synthesis and Histone Deacetylase Inhibitory Activity of New Benzamide Derivatives, Journal of Medicinal Chemistry, (1999), Vol. 42, pp. 3001-3003, American Chemical Society.
OM	TAUNTON, JACK et al., Synthesis of Natural and Modified Trapoxins, Useful Reagents for Exploring Histone Deacetylase Function, Journal of American Chemical Society, (1996), Vol. 118, pp. 10412-10422, American Chemical Society.
ON	UESATO, SHINICHI et al., Novel Histone Deacetylase Inhibitors: N-Hydroxycarboxamides Possessing a Terminal Bicyclic Aryl Group, Bioorganic & Medicinal Chemistry Letters, (2002), Vol. 12, pp. 1347-1349, Elsevier Science Ltd.

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/682,496		
		Filing Date	October 9, 2003		
		First Named Inventor	Andrew B. Freistein		
		Group Art Unit	1626		
		Examiner Name	Not Yet Assigned		
Sheet	15	of	15	Attorney Docket Number	SYR-HDAC-5003-U

	OO	VAISBURG, ARKADII et al., (2-Amino-phenyl)-amides of ω -substituted alkanolic acids as net histone deacetylase inhibitors, Bioorganic & Medicinal Chemistry Letters, (2004), Vol. 14, pp. 283-287, Elsevier Ltd.	
	OP	VAN OMMESELAEGHE, K. et al., Amide Analogues of TSA: Synthesis, Binding Mode Analysis and HDAC Inhibition, Bioorganic & Medicinal Chemistry Letters, (2003), Vol. 13, pp. 1861-1864, Elsevier Science Ltd.	
	OQ	VASUDEVAN, ANIL et al., Heterocyclic Ketones as Inhibitors of Histone Deacetylase, Bioorganic & Medicinal Chemistry Letters, (2003), pp. 1-5, Elsevier Ltd.	
	OR	WANG, DI-FEI et al., QSAR Studies of PC-3 cell line inhibition activity of TSA and SAHA-like hydroxamic acids, Bioorganic & Medicinal Chemistry Letters, (2004), Vol. 14, pp. 707-711, Elsevier-Ltd.	
	OS	WITTICH, SYBILLE et al., Structure—Activity Relationships on Phenylalanine-Containing Inhibitors of Histone Deacetylase: In Vitro Enzyme Inhibition, Induction of Differentiation, and Inhibition of Proliferation in Friend Leukemic Cells, Journal of Medicinal Chemistry, (2002), Vol. 45, pp. 3296-3309, American Chemical Society.	
	OT	WONG, JASON C. et al., Structural Biasing Elements for In-Cell Histone Deacetylase Paralog Selectivity, Journal of American Chemical Society, (04/16/2003), Vol. 125, pp. 5586-5587, American Chemical Society.	
	OU	WOO, SOON HYUNG et al., Structurally Simple Trichostatin A-Like Straight Chain Hydroxamates as Potent Histone Deacetylase Inhibitors, Journal of Medicinal Chemistry, (2002), Vol. 45, pp. 2877-2885, American Chemical Society.	
	OV	WU, TOM Y. H. et al., Design, synthesis, and activity of HDAC inhibitors with a N-formyl hydroxylamine head group, Bioorganic & Medicinal Chemistry Letters, (2004), Vol. 14, pp. 449-453, Elsevier Ltd.	
	OW	YUREK-GEORGE, ALEXANDER et al., Total Synthesis of Spiruchostatin A, a Potent Histone Deacetylase Inhibitor, Journal of American Chemical Society, (2003), Vol. 126, pp. 1030-1031, American Chemical Society.	
	OX	ZHANG, YUBIN et al., Histone Deacetylase Inhibitors FK228, N-(2-ANINOPHENYL)-4-[N-(PYRIDIN-3-YL-METHOXYCARBONYL) AMINO-METHYL]BENZAMIDE AND m-CARBOXYCINNAMIC ACID BIS-HYDROXAMIDE AUGMENT RADIATION-INDUCED CELL DEATH IN GASTROINTESTINAL ADENOCARCINOMA CELLS, Int. Journal of Cancer, (2004) Vol. 110, pp. 301-308, Wiley InterScience.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.